Merck reported strong Q3 results with increased revenues and optimistic full-year guidance, driven by successful KEYTRUDA launches and multiple FDA approvals. Despite near-term challenges from patent expiries, the positive outlook on key growth drivers is likely to bolster investor confidence in the short term.

[1]